Guillermet-Guibert obtained her Master degree in Molecular and Cellular Biology from Ecole Normale Supérieure de Lyon, France, followed by a Ph.D. in Innovative Pharmacology from the University Paul Sabatier, Toulouse, France. She carried out Ph.D. work on somatostatin G protein-coupled receptor signalling in pancreatic cancer in INSERM Laboratory. In 2005, she undertook postdoctoral research in the laboratory of Prof. B. Vanhaesebroeck, Ludwig Institute for Cancer Research, where she discovered that the p110β isoform of PI3K signals downstream of G‐protein coupled receptors rather than tyrosine‐kinase receptors. Julie joined INSERM as a Group Leader in 2010. Her group is investigating the role of cell signalling pathways in pancreatic and ovarian tumoral biology, focusing mainly on non-mutated ubiquitous PI3K enzymes.
- Institut national de la santé et de la recherche médicale (INSERM)